CA-BESSEMER-VENTURE
25.2.2021 23:42:10 CET | Business Wire | Press release
Bessemer Venture Partners, a global early-stage venture capital firm, today announced the close of two new funds, adding $3.3 billion of capital for investing in promising technology companies at their early and subsequent growth stages.
Additionally, the firm welcomed five new partners, including Jeff Blackburn, who joins Bessemer Venture Partners from Amazon, alongside the promotion of existing Bessemer investors Mary D'Onofrio, Mike Droesch, Tess Hatch, and Andrew Hedin.
“Today marks an incredible milestone at Bessemer as we launch our latest and largest funds and add five exceptional investors into the partnership,” said Jeremy Levine, a partner in Bessemer’s New York office. “I’m proud to celebrate the success of Mary, Mike, Tess, and Andrew, and I am excited to welcome Jeff to the firm. Having known Jeff for 15 years, I’m a great admirer of his stunning track record as an innovator and leader paired with his deep humility. I know his peerless experience leading one of the world’s greatest tech and consumer brands will benefit our team and the many founders who partner with Bessemer.”
Blackburn joins Bessemer following a 22-year career at Amazon, first joining the e-commerce giant after its IPO and then spearheading its growth in the core marketplace business and expansion across Amazon Advertising, Prime Video, Amazon Music, and Amazon Studios. Most recently, Blackburn served as senior vice president of worldwide business development. He oversaw dozens of Amazon’s minority investments and more than a hundred acquisitions across all business lines – including retail, Kindle, Echo, Alexa, FireTV, advertising, music, streaming audio & video, and Amazon Web Services.
At Bessemer, he will apply his innovative mindset and considerable experience -- as an investor, operator, and leader – toward existing and future Bessemer portfolio companies.
“Having been part of Amazon for more than two decades, I’m excited to begin a new chapter helping customer-focused founders build breakthrough companies,” said Blackburn. "I’ve known the Bessemer team for many years and have long admired their strategic vision and success backing early-stage ventures."
Blackburn’s arrival and the promotions of D'Onofrio, Droesch, Hatch, and Hedin all coincide with the close of Bessemer’s eleventh flagship fund, BVP XI, and their second opportunity fund, BVP Century II. The majority of the $3.3 billion across both funds will focus on early-stage investments, consistent with the firm’s time-honored approach of starting with seed and Series A investments and sticking with companies at every stage of their growth.
The firm continues to expand with a leadership team of 21 partners and over 45 investors, advisors, and platform team members positioned all over the world – Silicon Valley, San Francisco, Seattle, New York, Boston, London, Tel Aviv, Bangalore, and Beijing.
Bessemer Partner Byron Deeter added: “Our partners work one-on-one with our CEOs, but they also benefit from the growing scale and support from our entire platform. With our new funds and expanded partnership, Bessemer is even better equipped to help the best entrepreneurs – across all stages, sectors, and geographies – build incredible companies.”
About Bessemer Venture Partners
Bessemer Venture Partners is a global early-stage venture capital firm. With a portfolio of more than 200 companies, Bessemer helps visionary entrepreneurs lay strong foundations to create companies that matter, and supports them through every stage of their growth. The firm has backed more than 130 IPOs, including Shopify, Yelp, LinkedIn, Skype, LifeLock, Twilio, SendGrid, DocuSign, Wix, and Fiverr. Bessemer's team of investors and partners are positioned all over the world in Silicon Valley, San Francisco, Seattle, New York, Boston, Tel Aviv, Bangalore, and Beijing.
https://www.bvp.com/
Follow @BessemerVP
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225006258/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom